Dr. Hosni STA is the Founder and CEO of AcedrA BioPharmaceuticals, a Saudi-based company specialized in rare diseases and advanced therapies across the MENA region. A Doctor of Pharmacy with master’s degrees in Total Quality Management and Strategic Market Intelligence, Dr. STA also completed executive education at Imperial College and the London School of Economics in M&A and managerial finance. With over 15 years of experience in pharmaceuticals and biotech, he has built deep know-how in launching and scaling niche therapeutic products in highly regulated and fragmented markets. His expertise spans market access, regulatory pathways, pricing strategies, and business development for cell and gene therapies, CRISPR, ADCs, TKIs, and biosimilars. He has led over 30 product launches, set up regulatory infrastructures in 14 countries, and designed operational models for early access and expanded access programs. Dr. STA transformed AcedrA into the most active company in Saudi governmental procurement and a trusted partner for global companies entering the MENA region. His proven ability to navigate institutional, public, and private channels makes him a unique enabler for biotech partnerships in emerging markets. He is also a recognized speaker at global biotech events, including CAR-TCR Europe.